Skip to main content
Clinical Trials/NL-OMON38001
NL-OMON38001
Completed
N/A

Chemoradiation followed by surgery for patients with cT4 oesophageal cancer - TOR-study (T4 Oesophagus Resection)

Academisch Medisch Centrum0 sites30 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
oesophageal carcinoma
Sponsor
Academisch Medisch Centrum
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Histologically proven squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus or gastro esophageal junction
  • Surgical irresectable (T4a and T4b), as determined by Endoscopic Ultra Sound (EUS), CT scan of neck, thorax and abdomen OR Positon Emission Tomography (PET)\-scan, without distant metastasis (T4a: ingrowth in pleura, pericardium, diaphragm, or adjacent peritoneum, T4b other adjacent structures,e.g. aorta, vertebral body, trachea)

Exclusion Criteria

  • cT4b oesophageal carcinoma with tracheobronchial involvement, as demonstrated on bronchoscopy after neoadjuvant treatment
  • Past or current history of malignancy other than entry diagnosis except for non\-melanomatous skin cancer, or curatively treated in situ carcinoma of the cervix, or malignancy more than 5 years prior to enrollment
  • Pregnancy (positive serum pregnancy test) and lactation
  • Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) \<\= 1 year before enrollment
  • Active infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatment
  • Dementia or altered mental status that would prohibit the understanding and giving of informed consent
  • Inadequate caloric\- and/or fluid intake
  • Weight loss \> 15%.

Outcomes

Primary Outcomes

Not specified

Similar Trials